Wikipedia

Lysine acetylsalicylate

Lysine acetylsalicylate, also known as aspirin DL-lysine or lysine aspirin, is a more soluble form of acetylsalicylic acid (aspirin). As with aspirin itself, it is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory, antithrombotic and antipyretic properties.[1] It is composed of the ammonium form of the amino acid lysine paired with the conjugate base of aspirin.

Lysine acetylsalicylate
Identifiers
CAS Number
PubChem CID
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC15H22N2O6
Molar mass326.349 g·mol−1
3D model (JSmol)
  • CC(=O)OC1=CC=CC=C1C(=O)[O-].C(CC[NH3+])CC(C(=O)O)N
  • InChI=1S/C9H8O4.C6H14N2O2/c1-6(10)13-8-5-3-2-4-7(8)9(11)12;7-4-2-1-3-5(8)6(9)10/h2-5H,1H3,(H,11,12);5H,1-4,7-8H2,(H,9,10)
  • Key:JJBCTCGUOQYZHK-UHFFFAOYSA-N

Lysine acetylsalicylate was developed for intravenous administration in acute pain management, enabling faster onset of action compared to oral aspirin.[2] Adverse effects are similar to those of orally administered aspirin, including upset stomach, and heartburn.[3] In more serious cases, it can cause peptic ulcers, gastric bleeding, and exacerbate asthma. Due to its antithrombotic properties, patients using lysine acetylsalicylate or oral aspirin have an increased risk of bleeding especially for patients on blood thinning medications. It should not be used in children with infections, as it poses a risk of Reye syndrome, nor should it be used in the final trimester of pregnancy due to risks of premature closure of the foramen ovale in the fetal heart.

The therapeutic effects of salicylic acids were first documented in 1763 by Edward Stone, with acetylsalicylic acid being synthesized by Felix Hoffmann, a chemist working under Bayer, in 1897.[4] Acetylsalicylic acid-derived salt compounds were first discovered in 1970,[5] and the synthesis of lysine acetylsalicylate was first documented in 1978.[6]

Mechanism of action

edit

Lysine acetylsalicylate is considered a prodrug, requiring it to be metabolized before displaying its therapeutic properties. After administration, lysine acetylsalicylate is hydrolyzed, separating into lysine and acetylsalicylate compounds.[7]

Cyclo-oxygenase enzyme (COX) inhibition

edit

Two forms of COX enzymes have been identified, COX-1 and COX-2. COX enzymes are responsible for catalyzing the conversion of arachidonic acid to prostaglandins, which are used as precursors for other substances, in particular thromboxane A2.[8] Thromboxane A2 is a potent platelet activator, inducing changes in platelets that ultimately promote aggregation and the formation of clots. Thromboxane A2 also displays vasoconstrictor properties by acting on vascular smooth muscle cells.[9] Prostaglandins are also important mediators of the inflammatory response, with high levels of prostaglandins being seen in inflamed tissues.[10]

Acetylsalicylate compounds act as inhibitors of COX-1 and COX-2 enzyme activity, enabling the drug to display its antiplatelet and anti-inflammatory properties.[11] The compound irreversibly suppresses COX-1 activity by addition of an acetyl group to a serine amino acid.[11] This disables the binding mechanism of arachidonic acid, inhibiting the synthesis of prostaglandins and thromboxane A2 which stops platelet aggregation and inflammation. The same mechanism is also shown in COX-2 enzymes, albeit with lower efficiency of binding.[11]

Other proposed mechanisms

edit

Acetylsalicylate compounds are also thought to have other mechanisms that exert anti-inflammatory effects on cells, which are mainly prostaglandin-independen.t[12] Acetylsalicylate inhibits neutrophil activation by desensitizing them to endogenous chemical signals such as leukotrienes, stopping the inflammatory cascade.[13] Acetylsalicylate also reduces the expression of nitric oxide synthase,[12] obstructing the synthesis of nitric oxide compounds. Nitric oxide plays a key role in inflammation by activating macrophages and regulating apoptosis.[12][14] Acetylsalicylate also inhibits the activation of nuclear factor kappa-B, which decreases the expression of pro-inflammatory molecules such as interleukins.[15]

Chemical properties

edit

Lysine acetylsalicylate exists as a white, crystalline substance displaying weakly acidic properties. Lysine acetylsalicylate is generally unstable in a basic medium, readily undergoing a multi-step hydrolysis reaction that is catalyzed by the presence of negatively charged hydroxide ions.[citation needed] The primary target of the hydrolysis reaction is the ester group, dissociating into a carboxylic acid and aromatic alcohol.[citation needed]

Synthesis

edit

The synthesis of lysine acetylsalicylate requires the precursor sodium salicylate, another salt of salicylic acid. Sodium salicylate is prepared by adding acetylsalicylic acid to a solution of sodium hydrogen carbonate.[citation needed] The solution is then stirred and filtered to produce sodium salicylate crystals, which are dried to remove water.[citation needed]

Sodium salicylate can be synthesized into acetylsalicylate through two methods. The first method is through mixing a 30% sodium salicylate solution with lysine, and heating the mixture under reflux for 40 minutes.[citation needed] Next, the solution is cooled and heated again to evaporate the resulting water. When a precipitate is noticed, the solution is put into a refrigerator until fully crystallized, with the resulting crystals being lysine acetylsalicylate.[citation needed] The second method involves the same process, but the mixture is not initially heated and is instead left at room temperature for 48 hours. Method 1 is noted to obtain a greater yield of lysine acetylsalicylate.[16]

Pharmacokinetics

edit

Lysine acetylsalicylate is normally administered intravenously into the blood due to its high water solubility when compared to only acetylsalicylate. This enables aspirin to be released directly into blood circulation, bypassing the need for absorption through the stomach as well as liver metabolism.[17]

When compared to oral doses of aspirin, lysine acetylsalicylate displays a greater antiplatelet and anti-inflammatory response. Additionally, lysine acetylsalicylate shows a faster onset of action when compared to oral aspirin of an equivalent dose.[18] Lysine acetylsalicylate also displays a shorter mean residence time in the body (0.37 hours) as well as a shorter elimination half-life (17 minutes) when administered intravenously, which could indicate that it displays a shorter duration of exposure. Lysine acetylsalicylate also provides less interpatient variability in antiplatelet properties.[19]

Acetylsalicylate is predominantly metabolized through a conjugation reaction with glycine to form salicyluric acid. Salicyluric acid also acts as the main compound of aspirin excretion, with 98% of aspirin being secreted via this pathway by the kidney. Salicyluric acid can undergo further metabolism to form glucuronide compounds, or hydroxylation to form gentisic acid (1% of total aspirin).[20][21]

Medical uses

edit

Lysine acetylsalicylate is used acutely in an inpatient setting, for conditions presenting with severe pain, particularly acute migraine attacks and severe headache.[22] It is also used as an ultra-rapid platelet blockade agent for intra-procedural clearance of thrombus, and among patients with an urgent need for antiplatelet therapy without feasible nasogastric or oral access.[23] These include, but are not limited to: patients with acute ischemic stroke, arterial dissection, and those undergoing endovascular stent placement.[23]

Pain

edit

In an inpatient setting, lysine acetylsalicylate has been shown to be safe and effective in the inpatient management of severe headache and migraine.[22] Two randomized trials found that when combined with metoclopramide, lysine acetylsalicylate has comparable efficacy to sumatriptan for migraine.[24]

Antiplatelet

edit

Clinical trials on the use of lysine acetylsalicylate as an antiplatelet for acute coronary syndrome and chronic coronary syndrome finds comparable efficacy of lysine acetylsalicylate to oral aspirin.[25][18][26][27] The economic efficiency of using lysine acetylsalicylate in the secondary prevention of ischemic stroke and myocardial infarction has also been demonstrated in one pharmacoeconomic study.[28] Lysine acetylsalicylate is generally reserved for patients with urgent need of antiplatelet therapy with no oral or nasogastric access.[23] However, its rapid onset through IV administration makes it applicable for thrombus clearance during stent placement and other surgical procedures.[23]

Diagnosis of NSAID-exacerbated respiratory disease

edit

NSAID-exacerbated respiratory disease refers to the combination of NSAID intolerance, asthma, with chronic rhinosinusitis with nasal polyposis.[29] Lysine acetylsalicylate is used as a challenge test to diagnose NSAID-exacerbated respiratory disease. Drops of lysine acetylsalicylate are instilled via pipette or spray to both nostrils. Patients with NSAID-exacerbated respiratory disease had a significant increase in symptoms compared to those without NSAID-exacerbated respiratory disease.[30][31]

Side effects

edit

Contraindications

edit

All NSAIDs, including aspirin, should be avoided 20 weeks or later in pregnancy to prevent risk of kidney problems in unborn babies.[32] Due to linkage with Reye syndrome, aspirin should not be used in children under the age of 16 showing signs of recovering from infection.[33] Those who are allergic to, or intolerant of NSAIDs such as ibuprofen and naproxen should not use lysine acetylsalicylate.[34] Lysine acetylsalicylate is avoided in patients with Glucose-6-phosphate dehydrogenase deficiency due to the risk of hemolytic anemia.[35]

Gastrointestinal

edit

Non-selective blockade of COX by NSAIDs such as lysine acetylsalicylate results in the attenuation of gastric defense, resulting in an increased risk of gastrointestinal bleeding.[36] As such, lysine acetylsalicylate should be used with caution in patients with peptic ulcer or gastritis.[34] Combining aspirin with other NSAIDs has been shown to drastically increase the risk of gastrointestinal bleeding and should be done with caution.[37]

Asthma and NSAID-exacerbated respiratory disease

edit

Blockade of COX-1 increases activation of the leukotriene pathway, resulting in the release of cysteinyl leukotrienes which are potent bronchoconstrictors.[38] Leukotriene is also a major factor in the pathogenesis of asthma.[39] As such, caution should be applied in the use of lysine acetylsalicylate in patients with asthma.

Similarly, the increase in cysteinyl leukotrienes can also cause hyperreactivity in healthy patients, leading to NSAID-exacerbated respiratory disease.[40] Lysine acetylsalicylate should be used with caution in patients diagnosed with NSAID-exacerbated respiratory disease.

Bleeding

edit

Owing to its antiplatelet properties, use of oral aspirin and lysine acetylsalicylate will increase the risk of bleeding. As such, patients with hemophilia or other bleeding tendencies should not use oral aspirin nor lysine acetylsalicylate.[34] The risk of bleeding is increased for those using warfarin and alcohol.[34]

References

edit
  1. ^ "Lysine acetylsalicylate". go.drugbank.com. Retrieved 2023-03-14.
  2. ^ "Lysine Acetylsalicylate - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 2023-03-14.
  3. ^ Abramson SB (2021-04-21). Furst DE, Seo P (eds.). "Aspirin: mechanism of action, major toxicities, and use in rheumatic diseases". UptoDate. Waltham (MA): Wolters Kluwer N.V. Retrieved 2023-03-14.
  4. ^ Montinari MR, Minelli S, De Caterina R (February 2019). "The first 3500 years of aspirin history from its roots - A concise summary". Vascular Pharmacology. 113: 1–8. doi:10.1016/j.vph.2018.10.008. PMID 30391545. S2CID 53215011.
  5. ^ DE 2156806, "Arginine acetylsalicylates, processes for their production and pharmaceutical preparations containing them", issued 28 April 1983, assigned to METABIO, Boulogne (Frankreich). 
  6. ^ ES 456529A1, "Procedure for preparing lycine acetilsalicilate.", issued 1 February 1978, assigned to Egyb SA. 
  7. ^ Dinis-Oliveira RJ, Pontes H, Bastos ML, Remião F, Duarte JA, Carvalho F (January 2009). "An effective antidote for paraquat poisonings: the treatment with lysine acetylsalicylate". Toxicology. 255 (3): 187–193. Bibcode:2009Toxgy.255..187D. doi:10.1016/j.tox.2008.10.015. PMID 19026709.
  8. ^ Tóth L, Muszbek L, Komáromi I (March 2013). "Mechanism of the irreversible inhibition of human cyclooxygenase-1 by aspirin as predicted by QM/MM calculations". Journal of Molecular Graphics & Modelling. 40: 99–109. doi:10.1016/j.jmgm.2012.12.013. PMID 23384979.
  9. ^ Rucker D, Dhamoon AS (2022). "Physiology, Thromboxane A2". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 30969639. Retrieved 2023-03-14.
  10. ^ Ricciotti E, FitzGerald GA (May 2011). "Prostaglandins and inflammation". Arteriosclerosis, Thrombosis, and Vascular Biology. 31 (5): 986–1000. doi:10.1161/ATVBAHA.110.207449. PMC 3081099. PMID 21508345.
  11. ^ a b c Demir DM (2011). Aspirin : therapeutic uses, adverse effects, and pharmacokinetics. Nova Science Publishers. ISBN 978-1-61324-578-1. OCLC 712114782.
  12. ^ a b c Amin AR, Vyas P, Attur M, Leszczynska-Piziak J, Patel IR, Weissmann G, Abramson SB (August 1995). "The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase". Proceedings of the National Academy of Sciences of the United States of America. 92 (17): 7926–7930. Bibcode:1995PNAS...92.7926A. doi:10.1073/pnas.92.17.7926. PMC 41259. PMID 7544010.
  13. ^ Abramson S, Korchak H, Ludewig R, Edelson H, Haines K, Levin RI, et al. (November 1985). "Modes of action of aspirin-like drugs". Proceedings of the National Academy of Sciences of the United States of America. 82 (21): 7227–7231. Bibcode:1985PNAS...82.7227A. doi:10.1073/pnas.82.21.7227. PMC 390822. PMID 2997778.
  14. ^ Sharma JN, Al-Omran A, Parvathy SS (December 2007). "Role of nitric oxide in inflammatory diseases". Inflammopharmacology. 15 (6): 252–259. doi:10.1007/s10787-007-0013-x. PMID 18236016. S2CID 9722076.
  15. ^ Kopp E, Ghosh S (August 1994). "Inhibition of NF-kappa B by sodium salicylate and aspirin". Science. 265 (5174): 956–959. Bibcode:1994Sci...265..956K. doi:10.1126/science.8052854. PMID 8052854.
  16. ^ Chen K, Zhu X, Tian Q, Zhang L (December 2019). "Improvement of Synthetic Method of Lysine Aspirin". IOP Conference Series: Materials Science and Engineering. 677 (2): 022054. Bibcode:2019MS&E..677b2054C. doi:10.1088/1757-899x/677/2/022054. ISSN 1757-8981. S2CID 214103504.
  17. ^ Schrör K (2008-11-12). Acetylsalicylic Acid (1 ed.). Wiley. doi:10.1002/9783527625994. ISBN 978-3-527-32109-4. S2CID 250381963.
  18. ^ a b Vivas D, Martín A, Bernardo E, Ortega-Pozzi MA, Tirado G, Fernández C, et al. (May 2015). "Impact of Intravenous Lysine Acetylsalicylate Versus Oral Aspirin on Prasugrel-Inhibited Platelets: Results of a Prospective, Randomized, Crossover Study (the ECCLIPSE Trial)". Circulation: Cardiovascular Interventions. 8 (5). doi:10.1161/circinterventions.114.002281. PMID 25957056. S2CID 11763813.
  19. ^ Ito S, Oka R, Tsuchida A, Yoshioka H (1991). "Disposition of single-dose intravenous and oral aspirin in children". Developmental Pharmacology and Therapeutics. 17 (3–4): 180–186. doi:10.1159/000457520. PMID 1841835.
  20. ^ Levy G (July 1965). "Pharmacokinetics of salicylate elimination in man". Journal of Pharmaceutical Sciences. 54 (7): 959–967. doi:10.1002/jps.2600540703. PMID 5862532.
  21. ^ Shen J, Wanwimolruk S, Purves RD, McQueen EG, Roberts MS (October 1991). "Model representation of salicylate pharmacokinetics using unbound plasma salicylate concentrations and metabolite urinary excretion rates following a single oral dose". Journal of Pharmacokinetics and Biopharmaceutics. 19 (5): 575–595. doi:10.1007/bf01062964. PMID 1783992. S2CID 5810747.
  22. ^ a b Weatherall MW, Telzerow AJ, Cittadini E, Kaube H, Goadsby PJ (September 2010). "Intravenous aspirin (lysine acetylsalicylate) in the inpatient management of headache". Neurology. 75 (12): 1098–1103. doi:10.1212/WNL.0b013e3181f39a11. PMID 20855853. S2CID 39322164.
  23. ^ a b c d "Lysine Acetylsalicylate - CHW Drug Protocol" (PDF). Sydney Children's Hospital Network. Children's Hospital of Westmead. 2022-03-05. Retrieved 2023-03-14.
  24. ^ Tfelt-Hansen P (2000). "The effectiveness of combined oral lysine acetylsalicylate and metoclopramide (Migpriv) in the treatment of migraine attacks. Comparison with placebo and oral sumatriptan". Functional Neurology. 15 (Suppl 3): 196–201. PMID 11200792.
  25. ^ Zhao Y, Shen LH, Yang M (December 2007). "[Efficacy of intravenous aspirin use in patients with acute coronary syndrome]". Zhonghua Xin Xue Guan Bing Za Zhi. 35 (12): 1126–1129. PMID 18341815.
  26. ^ Ferlini M, Leonardi S, Mandurino Mirizzi A, Montalto C, Crimi G, Repetto A, et al. (July 2021). "Oral aspirin or low dose of intravenous lysine acetylsalicylate in ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention". Journal of Cardiovascular Medicine. 22 (7): 539–545. doi:10.2459/jcm.0000000000001174. PMID 34076601. S2CID 233925029.
  27. ^ Gurfinkel EP, Altman R, Scazziota A, Heguilen R, Mautner B (September 2000). "Fast platelet suppression by lysine acetylsalicylate in chronic stable coronary patients. Potential clinical impact over regular aspirin for coronary syndromes". Clinical Cardiology. 23 (9): 697–700. doi:10.1002/clc.4960230912. PMC 6654778. PMID 11016021.
  28. ^ Marissal JP, Selke B, Lebrun T (August 2000). "Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate". PharmacoEconomics. 18 (2): 185–200. doi:10.2165/00019053-200018020-00008. PMID 11067652. S2CID 43759842.
  29. ^ Laidlaw TM, Israel E (31 October 2022). Barnes PJ, Corren J, Feldweg AM, Dieffenbach P (eds.). "Aspirin-exacerbated respiratory disease". UpToDate. Wolters Kluwer N.V. Retrieved 2023-03-14.
  30. ^ Casadevall J, Ventura PJ, Mullol J, Picado C (November 2000). "Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry". Thorax. 55 (11): 921–924. doi:10.1136/thorax.55.11.921. PMC 1745635. PMID 11050260.
  31. ^ Verge J (2018-05-23). "Basophil response evaluation in patients with NSAID-exacerbated respiratory disease (NERD) after nasal provocation test with lysine-aspirin (NPT-Lysine)". doi:10.26226/morressier.5acdc661d462b8029238dadb. Retrieved 2023-03-14. {{cite journal}}: Cite journal requires |journal= (help)
  32. ^ "Yellow fever vaccine shortages could be on the cards, warns WHO". Pharmaceutical Journal. 2016. doi:10.1211/pj.2016.20201142. ISSN 2053-6186.
  33. ^ "Reye's syndrome - Symptoms and causes". Mayo Clinic. Retrieved 2023-03-14.
  34. ^ a b c d "Aspirin Uses, Dosage, Side Effects & Interactions". Drugs.com. Retrieved 2023-03-14.
  35. ^ Roberts DF, Livingstone FB (June 1986). "Frequencies of Hemoglobin Variants: Thalassemia, the Glucose-6-Phosphate Dehydrogenase Deficiency, G6PD Variants, and Ovalocytosis in Human Populations". Man. 21 (2): 351. doi:10.2307/2803169. ISSN 0025-1496. JSTOR 2803169.
  36. ^ Sørensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, Olsen JH (September 2000). "Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin". The American Journal of Gastroenterology. 95 (9): 2218–2224. doi:10.1111/j.1572-0241.2000.02248.x. PMID 11007221. S2CID 33742424.
  37. ^ Delaney JA, Opatrny L, Brophy JM, Suissa S (August 2007). "Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding". CMAJ. 177 (4): 347–351. doi:10.1503/cmaj.070186. PMC 1942107. PMID 17698822.
  38. ^ Picado C (May 2006). "Mechanisms of aspirin sensitivity". Current Allergy and Asthma Reports. 6 (3): 198–202. doi:10.1007/s11882-006-0035-2. PMID 16579869. S2CID 29014368.
  39. ^ Berger A (July 1999). "What are leukotrienes and how do they work in asthma?". BMJ. 319 (7202): 90. doi:10.1136/bmj.319.7202.90. PMC 1116241. PMID 10398630.
  40. ^ Woo SD, Luu QQ, Park HS (2020). "NSAID-Exacerbated Respiratory Disease (NERD): From Pathogenesis to Improved Care". Frontiers in Pharmacology. 11: 1147. doi:10.3389/fphar.2020.01147. PMC 7399220. PMID 32848759.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Lysine_acetylsalicylate&oldid=1259072111"